Eleni Zerva

Eleni Zerva

Auto-generated profile, based on publicly available information

Eleni Zerva

Aix Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, 13288 Marseille, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Science Advances
Verified
Journal Article
Open access
XLXi Liu
Xi Liu
DDDinesh Dhumal
Dinesh Dhumal
PCPatricia Santofimia Castaño
Patricia Santofimia Castaño
JLJuan Liu
Juan Liu
MCMarion Casanova
Marion Casanova
LPLing Peng
Ling Peng
Cardiotoxicity, especially human ether-a-go-go–related gene (hERG)–related toxicity, is a leading cause of drug failure or market withdrawal. Reducing hERG binding to obviate potential cardiac toxicity is crucial. Nanotechnology has been applied to drug delivery for reducing drug toxicity and improving efficacy, but few studies have addressed hERG-related cardiotoxicity. We report the use of self-assembling dendrimer nanosystems for drug formulation and delivery, which effectively reduced hERG binding and associated toxicity while promoting therapeutic efficacy. Specifically, these dendrimer nanosystems efficiently encapsulated the antimalarial drug chloroquine, the anticancer agent doxorubicin, and the NUPR1 inhibitor ZZW115, all three having high affinity to hERG channels. These nanoformulations showed three- to eightfold reduced hERG binding affinity, which, in animal models, translated to abolished toxicity. These nanodrugs exhibited prolonged circulation, leading to enhanced accumulation at disease sites and improved treatment outcomes. This study highlights the potential of nanotechnology to reduce hERG binding and related toxicity while improving drug efficacy, offering valuable perspectives for drug development.

31 January 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
Dimitra Ioanna LampropoulouDimitra Ioanna Lampropoulou
Dimitra Ioanna Lampropoulou
VBVanessa Meletia Bala
Vanessa Meletia Bala
EZEleni Zerva
Eleni Zerva
EPEvangelia Pliakou
Evangelia Pliakou
DFDIMITRIOS FILIPPOU
DIMITRIOS FILIPPOU
GAGerasimos Aravantinos
Gerasimos Aravantinos
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments. Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection. Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients. Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.